Harbor Capital Advisors Inc. Acquires 6,938 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Harbor Capital Advisors Inc. raised its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 4.8% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 152,317 shares of the medical equipment provider's stock after purchasing an additional 6,938 shares during the period. Lantheus accounts for approximately 0.7% of Harbor Capital Advisors Inc.'s investment portfolio, making the stock its 16th biggest position. Harbor Capital Advisors Inc. owned approximately 0.22% of Lantheus worth $14,866,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Janus Henderson Group PLC boosted its stake in shares of Lantheus by 72.7% in the 4th quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider's stock valued at $554,583,000 after purchasing an additional 2,610,118 shares during the last quarter. Farallon Capital Management LLC lifted its holdings in Lantheus by 79.9% in the fourth quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider's stock valued at $475,590,000 after buying an additional 2,361,000 shares during the period. T. Rowe Price Investment Management Inc. boosted its position in Lantheus by 40.5% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider's stock valued at $135,025,000 after acquiring an additional 435,445 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in Lantheus by 2.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,347,082 shares of the medical equipment provider's stock worth $120,510,000 after acquiring an additional 30,891 shares during the period. Finally, Silvercrest Asset Management Group LLC grew its holdings in Lantheus by 39.1% during the 4th quarter. Silvercrest Asset Management Group LLC now owns 973,888 shares of the medical equipment provider's stock worth $87,124,000 after acquiring an additional 273,838 shares during the period. 99.06% of the stock is owned by institutional investors and hedge funds.

Lantheus Trading Down 3.4%

NASDAQ LNTH traded down $2.80 during mid-day trading on Tuesday, hitting $80.42. The company's stock had a trading volume of 1,190,596 shares, compared to its average volume of 1,005,563. The company's 50 day simple moving average is $89.97 and its 200 day simple moving average is $91.69. Lantheus Holdings, Inc. has a twelve month low of $73.11 and a twelve month high of $126.89. The firm has a market capitalization of $5.56 billion, a price-to-earnings ratio of 13.38 and a beta of 0.11.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The company had revenue of $372.76 million for the quarter, compared to analyst estimates of $377.37 million. During the same quarter last year, the firm posted $1.69 EPS. Lantheus's revenue for the quarter was up .8% on a year-over-year basis. As a group, research analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Insider Buying and Selling at Lantheus

In other news, Director Mary Anne Heino sold 26,066 shares of the stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $76.83, for a total transaction of $2,002,650.78. Following the completion of the transaction, the director now directly owns 318,650 shares of the company's stock, valued at $24,481,879.50. This represents a 7.56% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the sale, the chief financial officer now owns 113,860 shares of the company's stock, valued at approximately $11,445,207.20. The trade was a 8.07% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 36,068 shares of company stock worth $3,008,051. Corporate insiders own 1.50% of the company's stock.

Analyst Ratings Changes

LNTH has been the topic of a number of recent analyst reports. B. Riley dropped their price objective on Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a research note on Friday, March 21st. Wall Street Zen raised Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. Finally, Truist Financial cut their price target on Lantheus from $127.00 to $117.00 and set a "buy" rating on the stock in a report on Thursday, May 8th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $132.67.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.